United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC grew its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 29.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 752 shares of the biotechnology company’s stock after buying an additional 169 shares during the quarter. GAMMA Investing LLC’s holdings in United Therapeutics were worth $265,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ClariVest Asset Management LLC grew its holdings in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. Brooklyn Investment Group acquired a new stake in United Therapeutics during the third quarter worth about $33,000. Capital Performance Advisors LLP purchased a new position in United Therapeutics during the third quarter worth about $82,000. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics in the 3rd quarter valued at about $90,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on UTHR. The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $370.86.

Insider Transactions at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total value of $2,855,916.18. Following the sale, the chief financial officer now directly owns 6,426 shares in the company, valued at $2,358,277.74. This trade represents a 54.77 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 142,422 shares of company stock valued at $53,498,732. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Up 2.0 %

Shares of UTHR stock opened at $362.33 on Wednesday. The firm has a 50 day moving average of $370.72 and a two-hundred day moving average of $351.66. The stock has a market capitalization of $16.18 billion, a PE ratio of 15.91, a P/E/G ratio of 1.05 and a beta of 0.57. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the business posted $5.38 earnings per share. United Therapeutics’s revenue was up 22.9% compared to the same quarter last year. Analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.